Gossamer Bio (GOSS) COO/CFO Bryan Giraudo Receives Awards

What Happened

• Bryan Giraudo, COO and CFO of Gossamer Bio (GOSS), received derivative awards on August 24, 2026: 25 shares of Series A‑1 non‑voting convertible preferred stock at $1,000.00 per share (total cash paid $25,000) and 5,800,051 pre‑funded warrants reported at $0.00.
• These are acquisition/award transactions (Form 4 code A). They are derivative instruments (preferred shares and pre‑funded warrants), not immediate common‑stock purchases or open‑market sales.

Key Details

• Transaction date: 2026-08-24; Form 4 filed: 2026-08-26 (appears timely).
• 25 Series A‑1 preferred shares @ $1,000.00 each = $25,000 total.
• 5,800,051 pre‑funded warrants reported at $0.00 (no immediate cash value recorded on the Form 4).
• Shares owned after transaction: not specified in the supplied summary of the filing.
• Notable footnotes from the filing:
  • F1: Each Series A‑1 preferred share converts (upon stockholder approval) into common stock at a conversion amount equal to $1,000 ÷ $0.14 (per the Certificate of Designation).
  • F2: The pre‑funded warrants have no expiration and are immediately exercisable; before stockholder approval they convert/exercise into Series A‑1 preferred shares, and after approval they are exercisable for common stock.
  • F3: The filing also includes option-vesting provisions (if applicable) tied to FDA approval of seralutinib: 50% vests on FDA approval, remainder vests monthly thereafter (or starts monthly vesting if approval not obtained within two years).

Context

• These grants are derivative instruments. They may convert or be exercised into common shares only under the terms described (and, in some cases, only after stockholder approval). That means the awards do not necessarily translate into immediate common‑stock ownership or sales.
• The pre‑funded warrants are a durable form of claim (no expiration) and can become common stock once the conditions in the footnotes are met; the preferred shares have a stated conversion mechanism into common stock.
• This is an acquisition/award by an insider (not a sale). As always, insider awards can reflect compensation or financing arrangements and are factual disclosures rather than a direct signal of sentiment.